الفهرس 
Title : Outcome of Lymphoblastic Lymphoma in Pediatric Cancer Patients. A Single Institutional Study
ContentsOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Background: Pediatric Non Hodgkin lymphoma is a diverse collection of malignant neoplasms arising from mature and immature lymphoid cells of either B-cell or T-cell origin. Lymphoblastic lymphomas are neoplasms of precursor T-cells or B-cells. The St. Jude staging system is the most widely used for staging of NHLs. Treatment of LBL has evolved over time from the standard lymphoma-like therapy to the intensive multi-drug ALL- derived protocols. Aim of work: To estimate the event free survival (EFS) & the overall survival (OS) of Lymphoblastic Lymphoma cases treated at the National Cancer Institute of Egypt during the period from 1st of January 2012 to 31st of December 2016. Also to detect the relation between different patients’ variables and survival outcomes and to outline the different toxicities of chemotherapy. Patients and methods: This is a retrospective study of patients with lymphoblastic lymphoma, 18 years old or less, diagnosed and treated at the National Cancer Institute of Egypt. Epidemiological data, work up, staging, response to treatment, major toxicities of treatment and final outcome were collected from the patients{u2019} files. Results: The study included 31 patients of which 4 lost follow up, so the total eligible patients for the survival analysis were 27 patients. The median age of diagnosis was 9 years (ranging from 2 to 17 years of age). The majority of patients were males (80.6%). The most common presentation was the presence of a mediastinal mass observed in 83.9% of the patients. The majority of patients were diagnosed as T-cell LBL (87.1%). Stage III was the most common presentation in 74.2% of patients. At the end of the study, the OS was 77.8% and the EFS was 74% which is slightly lower than other similar studies